Latest news with #PrincessMáximaCenterforPediatricOncology
The Irish Sun
02-07-2025
- Health
- The Irish Sun
‘Please pray' plea from family of brave Donegal boy getting treatment in the Netherlands for rare blood disorder
A BRAVE young Donegal boy is undergoing a life-saving bone marrow transplant in the Netherlands today. Advertisement 2 Zach and his family have recently travelled to the Netherlands to seek treatment for his rare disorder Credit: Family Handout The syndrome, which affects a person's bone marrow, progresses into Acute Myeloid Leukaemia if left untreated. His only chance of survival lies in a bone marrow transplant, which is not available in Ireland. The devastating health diagnosis came only a year after his mother Patrice was diagnosed with AML. The mother-of-four, who underwent chemotherapy and a bone transplant for her illness, still receives treatment. Advertisement READ MORE ON IRISH NEWS The family have since received a tremendous amount of support from relatives, friends and the local community in the last year and a half. Zach and his family And today his grandmother, Kateleen Rodgers posted online asking for support. She said: 'Please pray for my grandson Zach McCrossan today who is having his bone marrow transplant in the Netherlands and for his mammy Patrice as well.' Advertisement Most read in The Irish Sun Zach's is expected to remain an inpatient at the Princess Máxima Center for Pediatric Oncology in Utrecht, Netherlands for at least three months. Following his awful diagnosis a GoFundMe was set up in April by the family to cover the costs of Zach's treatment. FUNDS RAISED Within 24 hours the campaign raised over €122,500, smashing their target of €3,500. In response the family posted on social media saying: "Whether you donated, organised a fundraiser, offered a lift, dropped off meals, minded our other children, shared advice, or simply sent a message of encouragement Advertisement "We have felt every bit of your love and kindness. "It's because of you... our incredible circle of family, friends, neighbours, and strangers with big hearts... "That we're able to be by Zach's side as he begins treatment in the Princess Máxima Center in Utrecht." 2 Donegal native Zach McCrossan was recently diagnosed with a rare blood disorder known as Myelodysplastic Syndrome Credit: Family Handout Advertisement
The Irish Sun
14-06-2025
- Health
- The Irish Sun
‘Our hearts are full of hope' – Irish family begins journey to the Netherlands for 4-year-old boy's rare treatment
AN IRISH family have started their journey to the Netherlands this morning to seek health treatment for the four-year-old boy. Zach McCrossan, based in St Johnston in Donegal, was recently diagnosed with high-risk Myelodysplastic Syndrome (MDS), a rare blood disorder that progresses to Acute Myeloid Advertisement 2 Zach has been diagnosed with a rare blood disorder Credit: Social media collects And his only chance of survival is a bone marrow transplant, which is not available in Ireland. He has now been referred to the Princess Máxima Center for Pediatric Oncology in Utrecht, The family were doubly shocked by the news of his diagnosis, as his mother, Patrice, was diagnosed with acute myeloid leukaemia in January 2024. The 32-year-old was rushed to Advertisement READ MORE ON HSE Unfortunately, the transplant wasn't as successful as the family had wished and Patrice now travels regularly to In April, the family launched a campaign to support Zach through his "critical treatment" as well as keep their "family together" during this difficult time. The campaign was launched with the goal of €3,500, and in 24 hours it had raised over €122,500 - smashing their initial target. The funds raised will go towards travel, Advertisement Most read in Health Exclusive Today, they began their journey to the airport after meeting their target for seeking Zach's treatment for his rare blood disorder. In awe of the support the family have received from their local community and beyond, they posted an update on "This morning, we left home and began our journey to the Netherlands with Zach. "As we make our way to the airport and step into this next chapter, our hearts are full of hope, of emotion, and of deep gratitude. Advertisement 'FELT EVERY BIT OF YOUR LOVE' "To every single person, near and far, who has supported us: thank you. "Whether you donated, organised a fundraiser, offered a lift, dropped off meals, minded our other children, shared advice, or simply sent a message of encouragement… "We have felt every bit of your love and kindness. "It's because of you... our incredible circle of family, friends, neighbours, and strangers with big hearts... Advertisement "That we're able to be by Zach's side as he begins treatment in the Princess Máxima Center in Utrecht." The family stated that they will regularly update their socials, GoFundMe campaign, and dedicated website on Zach McCrossan's progress over the coming weeks and months. 2 The family started their journey to the Netherlands to get Zach the treatment he requires Credit: Social media collects
Business Wire
27-05-2025
- Health
- Business Wire
Preclinical Data on Circle Pharma's CID-078 Featured in Poster Presentation at Advances in Neuroblastoma Research Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on CID-078 at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C., May 25-28, 2025. The data, which explore the therapeutic potential of CID-078 in neuroblastoma (NB), were presented in a poster entitled: 'Cyclin A/B-RxL Inhibition as a Novel Therapeutic Strategy in Neuroblastoma' Dylan M.M. Jongerius et al. Poster #P010 The poster highlights the work of researchers from the Princess Máxima Center for Pediatric Oncology (Utrecht, the Netherlands), the Hopp Children's Cancer Center Heidelberg (KiTZ) (Heidelberg, Germany), and Circle Pharma, demonstrating the potent anti-tumor activity of CID-078 in preclinical neuroblastoma (NB) models. CID-078 is a first-in-class oral macrocycle cyclin A/B RxL inhibitor that selectively disrupts RxL-mediated interactions between cyclin A2/B1 and their substrates, a novel mechanism of action that targets cell cycle dysregulation in cancer. In neuroblastoma, where CDK-RB-E2F axis deregulation and oncogenic E2F activity are common, this mechanism is particularly relevant. Key Findings Presented: Potent Single agent CID-078 activity was observed across multiple neuroblastoma cell line models. Mechanism of action studies confirmed induction of DNA damage, G2/M arrest and the activation of the spindle assembly checkpoint (SAC). Deletion of CDKN2A sensitized cells to CID-078 suggesting CDKN2A status maybe be used as a potential patient stratification strategy. 'A greater understanding of the biology of neuroblastoma, the most common extra-cranial solid tumor diagnosed in children, has shown specific genomic alterations which deregulate the cell cycle leading to E2F activation,' said Michael C. Cox, PharmD, MHSc, BCOP, SVP and head of early development of Circle Pharma. 'Circle's collaboration with these two premier pediatric oncology research institutions has shown again the potential of our macrocycle platform to develop new therapies for historically challenging targets. The exciting CDKN2A deletion biomarker data, as well as the in vitro data in a pediatric tumor with a need for better treatments support our clinical development plans for CID-078.' The full poster is available here. About CID-078, Circle Pharma's Cyclin A/B RxL Inhibitor Program CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation. In biochemical and cellular studies, Circle Pharma's cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and Myt1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center phase 1 clinical trial (NCT06577987) is currently enrolling patients. About Circle Pharma, Inc. South San Francisco-based Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop therapies for cancer and other serious illnesses. The company's proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies for historically undruggable targets. Circle Pharma's pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. Its lead program, CID-078, a cyclin A/B-RxL inhibitor, is in a Phase 1 clinical trial (NCT06577987) for patients with advanced solid tumors. To learn more about Circle Pharma, please visit
Yahoo
27-05-2025
- Business
- Yahoo
Preclinical Data on Circle Pharma's CID-078 Featured in Poster Presentation at Advances in Neuroblastoma Research Meeting
SOUTH SAN FRANCISCO, Calif., May 27, 2025--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on CID-078 at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C., May 25-28, 2025. The data, which explore the therapeutic potential of CID-078 in neuroblastoma (NB), were presented in a poster entitled: "Cyclin A/B-RxL Inhibition as a Novel Therapeutic Strategy in Neuroblastoma"Dylan M.M. Jongerius et #P010 The poster highlights the work of researchers from the Princess Máxima Center for Pediatric Oncology (Utrecht, the Netherlands), the Hopp Children's Cancer Center Heidelberg (KiTZ) (Heidelberg, Germany), and Circle Pharma, demonstrating the potent anti-tumor activity of CID-078 in preclinical neuroblastoma (NB) models. CID-078 is a first-in-class oral macrocycle cyclin A/B RxL inhibitor that selectively disrupts RxL-mediated interactions between cyclin A2/B1 and their substrates, a novel mechanism of action that targets cell cycle dysregulation in cancer. In neuroblastoma, where CDK-RB-E2F axis deregulation and oncogenic E2F activity are common, this mechanism is particularly relevant. Key Findings Presented: Potent Single agent CID-078 activity was observed across multiple neuroblastoma cell line models. Mechanism of action studies confirmed induction of DNA damage, G2/M arrest and the activation of the spindle assembly checkpoint (SAC). Deletion of CDKN2A sensitized cells to CID-078 suggesting CDKN2A status maybe be used as a potential patient stratification strategy. "A greater understanding of the biology of neuroblastoma, the most common extra-cranial solid tumor diagnosed in children, has shown specific genomic alterations which deregulate the cell cycle leading to E2F activation," said Michael C. Cox, PharmD, MHSc, BCOP, SVP and head of early development of Circle Pharma. "Circle's collaboration with these two premier pediatric oncology research institutions has shown again the potential of our macrocycle platform to develop new therapies for historically challenging targets. The exciting CDKN2A deletion biomarker data, as well as the in vitro data in a pediatric tumor with a need for better treatments support our clinical development plans for CID-078." The full poster is available here. About CID-078, Circle Pharma's Cyclin A/B RxL Inhibitor Program CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation. In biochemical and cellular studies, Circle Pharma's cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and Myt1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center phase 1 clinical trial (NCT06577987) is currently enrolling patients. About Circle Pharma, Inc. South San Francisco-based Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop therapies for cancer and other serious illnesses. The company's proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies for historically undruggable targets. Circle Pharma's pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. Its lead program, CID-078, a cyclin A/B-RxL inhibitor, is in a Phase 1 clinical trial (NCT06577987) for patients with advanced solid tumors. To learn more about Circle Pharma, please visit View source version on Contacts Media Contact:Roslyn Patterson Phone: 650.825.4099 Email: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
